Latest News

EUSA Pharma completes acquisition of
Cytogen Corporation
9th May 2008. EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May.

EUSA Pharma divests monoclonal antibody research business
and early-stage oncology product
1st May 2008. EUSA Pharma announced today that it has divested its monoclonal antibody research business to the French company International Drug Development (IDD). Concurrently, EUSA has divested its recombinant L-asparaginase therapeutic research program for acute lymphoblastic leukemia to the Alizé Pharma Group.

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
11th March 2008. EUSA Pharma announced announced that it has entered into a definitive agreement to acquire all the outstanding shares of Cytogen Corporation (NASDAQ: CYTO) for $22.6 million.

Novel Rapydan® gains Marketing Authorisation in EU for the
Relief of Pain associated with Needle Puncture and Cannulation
25 February 2008. EUSA Pharma today announced that Rapydan® (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorisation in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure.

EUSA Pharma out-licences preclinical-stage human antibody
to GlaxoSmithKline for up to $44 million plus royalties
18 February 2008. EUSA Pharma today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales.

EUSA Pharma announces $30 million Debt Facility
12 December 2007. EUSA Pharma announces that it has entered into a $30 million debt facility offered by Merrill Lynch Capital.

EUSA Pharma announces successful conclusion of the EMR Procedure for Rapydan®
18 October 2007. EUSA Pharma announces the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007.

EUSA Pharma appoints President Europe
3 October 2007. EUSA Pharma appoints Ad van Beysterveldt as President Europe and member of the company’s Executive Committee.